US2018228912A1PendingUtilityA1

Novel immunogenic peptides

Assignee: IMCYSE SAPriority: Oct 17, 2014Filed: Oct 16, 2015Published: Aug 16, 2018

Est. expiryOct 17, 2034(~8.3 yrs left)· nominal 20-yr term from priority

Inventors:Jean-Marie Saint-Remy Vincent Carlier Luc Vander Elst David Burkhart

C07K 14/70539C07K 14/4713A61K 39/385A61P 25/00A61K 47/646A61K 2039/64A61K 2039/572C12N 5/0639A61K 2039/6031A61K 39/0008A61P 37/02

PatentIndex Score

Cited by

References

Claims

Abstract

The invention relates to isolated immunogenic peptides comprising a MHC class II T cell epitope, and immediately adjacent or separated from said epitope a H-X(0,2)-C-X(2)-[CST] or [CST]-X(2)-C-X(0,2)-H redox motif.

Claims

exact text as granted — not AI-modified

1 . An isolated immunogenic peptide of between 13 and 100 amino acids comprising a MHC class II T cell epitope of an antigen, and immediately adjacent or separated by at most 7 amino acids from said epitope a H-X(0,2)-C-X(2)-[CST] ([SEQ ID NO:78], [SEQ ID NO:90] or [SEQ ID NO:91]) or a [CST]-X(2)-C-X(0,2)-H ([SEQ ID NO:79], [SEQ ID NO:92] or [SEQ ID NO:93]) redox motif sequence for use as a medicament. 
     
     
         2 . The peptide for use according to  claim 1 , with the proviso that said antigen does not contain in its sequence said motif within a distance of 10 amino acids of said epitope. 
     
     
         3 . The peptide for use according to  claim 1 , with the proviso that said antigen does not contain in its sequence said motif. 
     
     
         4 . The peptide for use according to  claim 1 , wherein the motif is H-X-C-X(2)-[CST] [SEQ ID NO:90] or [CST]-X(2)-C-X-H [SEQ ID NO:92] redox motif sequence. 
     
     
         5 . The peptide for use according to  claim 1 , wherein the motif is H-C-X(2)-[CST] [SEQ ID NO:78] or [CST]-X(2)-C-H [SEQ ID NO:79] redox motif sequence. 
     
     
         6 . The peptide for use according to  claim 1 , wherein the motif is H-X(0,2)-C-X(2)-C([SEQ ID NO:80], [SEQ ID NO:96] or [SEQ ID NO:97]), or C-X(2)-C-X(0,2)-H ([SEQ ID NO:83], [SEQ ID NO:94] or [SEQ ID NO:95]). 
     
     
         7 . The peptide for use according to  claim 1 , wherein the motif is H-C-X(2)-C [SEQ ID NO:80] or C-X(2)-C-H [SEQ ID NO:83]. 
     
     
         8 . The peptide for use according to  claim 1 , wherein said peptide has a length of between 13 and 75 amino acids. 
     
     
         9 . The peptide for use according to  claim 1 , wherein said peptide has a length of between 13 and 50 amino acids. 
     
     
         10 . The peptide for use according to  claim 1 , wherein said peptide has a length of between 13 and 30 amino acids. 
     
     
         11 . The peptide for use according to  claim 1 , wherein the MHC class II T cell epitope, is separated from said motif by a sequence of at most 4 amino acids. 
     
     
         12 . The peptide for use according to  claim 1 , wherein the MHC class II T cell epitope, is separated from said motif by sequence of 2 amino acids. 
     
     
         13 . The peptide for use according to  claim 1 , wherein X within the redox motif is Gly or Pro. 
     
     
         14 . The peptide for use according to  claim 1 , wherein X within the redox motif is not Cys. 
     
     
         15 . The peptide for use according to  claim 1 , wherein X outside the redox motif is not Cys, Ser or Thr. 
     
     
         16 . The peptide for use in accordance with  claim 1  for use in the prevention or treatment of multiple sclerosis (MS). 
     
     
         17 . The peptide for use according to  claim 16 , where the antigen is an auto-antigen involved in multiple sclerosis. 
     
     
         18 . The peptide for use according to  claim 16 , wherein the auto-antigen is MOG. 
     
     
         19 . The peptide for use according to  claim 16 , wherein the peptide comprises the epitope sequence VVHLYRNGK [SEQ ID NO:3]. 
     
     
         20 . The peptide for use according to  claim 16 , wherein the peptide has the sequence HCPYCSRVVHLYRNGKD [SEQ ID NO:1], HxCPYCSRVVHLYRNGKD [SEQ ID NO: 115], or HxxCPYCSRVVHLYRNGKD [SEQ ID NO: 116]. 
     
     
         21 . The peptide for use in accordance with  claim 1  for use in the prevention or treatment diabetes. 
     
     
         22 . The peptide for use in accordance with  claim 21 , wherein the antigen is proinsulin. 
     
     
         23 . An isolated immunogenic peptide of between 13 and 100 amino acids comprising a MHC class II T cell epitope of an antigen, and immediately adjacent or separated by at most 7 amino acids from said epitope a H-X(0,2)-C-X(2)-[CST] ([SEQ ID NO:78] or [SEQ ID NO:90] or [SEQ ID NO:91]) or [CST]-X(2)-C-X(0,2)-H ([SEQ ID NO:79], [SEQ ID NO:92] or [SEQ ID NO:93] redox motif sequence, with the proviso that said antigen does not contain in its sequence said motif within a distance of 10 amino acids of said epitope. 
     
     
         24 - 42 . (canceled) 
     
     
         43 . A method for obtaining a population CD4+ T cells which are cytolytic against cells antigen, the method comprising the steps of:
 providing peripheral blood cells;   contacting said cells in vitro with an immunogenic peptide of between 13 and 100 amino acids comprising an MHC class II T cell epitope of an antigen, and immediately adjacent or separated by at most 7 amino acids from said epitope a H-X(0,2)-C-X(2)-[CST] ([SEQ ID NO:78], [SEQ ID NO:90] or [SEQ ID NO:91]) or a [CST]-X(2)-C-X(0,2)-H ([SEQ ID NO:79], [SEQ ID NO:92] or [SEQ ID NO:93]) redox motif sequence; and   expanding said cells in the presence of IL-2.   
     
     
         44 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.